PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.78%
Revenue growth above 1.5x AVGO's 4.00%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
11.98%
Gross profit growth above 1.5x AVGO's 4.94%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
24.51%
EBIT growth above 1.5x AVGO's 7.41%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
24.51%
Operating income growth above 1.5x AVGO's 7.41%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
21.84%
Net income growth at 50-75% of AVGO's 33.33%. Martin Whitman would question fundamental disadvantages in expenses or demand.
14.00%
EPS growth under 50% of AVGO's 33.33%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
18.75%
Diluted EPS growth at 50-75% of AVGO's 32.00%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
1.23%
Share count expansion well above AVGO's 1.26%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.00%
Diluted share reduction more than 1.5x AVGO's 1.21%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-51.00%
Negative OCF growth while AVGO is at 58.39%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-62.58%
Negative FCF growth while AVGO is at 62.61%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
517.81%
10Y revenue/share CAGR above 1.5x AVGO's 13.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
65.46%
5Y revenue/share CAGR above 1.5x AVGO's 13.16%. David Dodd would look for consistent product or market expansions fueling outperformance.
14.54%
3Y revenue/share CAGR 1.25-1.5x AVGO's 13.16%. Bruce Berkowitz might see better product or regional expansions than the competitor.
954.88%
10Y OCF/share CAGR above 1.5x AVGO's 68.33%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-33.39%
Negative 5Y OCF/share CAGR while AVGO is at 68.33%. Joel Greenblatt would question the firm’s operational model or cost structure.
-69.21%
Negative 3Y OCF/share CAGR while AVGO stands at 68.33%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
624.87%
Net income/share CAGR at 75-90% of AVGO's 705.69%. Bill Ackman would press for strategic moves to boost long-term earnings.
160.46%
Below 50% of AVGO's 705.69%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-17.86%
Negative 3Y CAGR while AVGO is 705.69%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
1627.00%
10Y equity/share CAGR above 1.5x AVGO's 70.62%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
115.78%
5Y equity/share CAGR above 1.5x AVGO's 70.62%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
36.06%
3Y equity/share CAGR at 50-75% of AVGO's 70.62%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.75%
Firm’s AR is declining while AVGO shows 2.15%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
19.10%
Inventory growth well above AVGO's 2.16%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
3.53%
Asset growth well under 50% of AVGO's 12.34%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
8.62%
50-75% of AVGO's 11.50%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-1.25%
We’re deleveraging while AVGO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
9.25%
R&D growth drastically higher vs. AVGO's 5.63%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
2.56%
SG&A growth of 2.56% while AVGO is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.